Use of Swedish smokeless tobacco during pregnancy: A systematic review of pregnancy and early life health risk.
Child health
epidemiology
pregnancy
public health
smokeless tobacco
snus
Journal
Addiction (Abingdon, England)
ISSN: 1360-0443
Titre abrégé: Addiction
Pays: England
ID NLM: 9304118
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
received:
04
05
2022
accepted:
29
11
2022
medline:
4
4
2023
pubmed:
17
12
2022
entrez:
16
12
2022
Statut:
ppublish
Résumé
Smokeless tobacco is a heterogeneous product group with diverse composition and prevalence globally. Tobacco use during pregnancy is concerning due to the risk of adverse pregnancy outcomes and effects on child health. Nicotine may mediate several of these effects. This systematic review measured health outcomes from Swedish smokeless tobacco (snus) use during pregnancy. Literature search was conducted by an information specialist in May 2022. We included human studies of snus use during pregnancy compared with no tobacco use, assessed risk of bias, conducted a meta-analysis and assessed confidence in effect-estimates using Grading of Recommendations, Assessment, Development and Evaluations (GRADE). We included 18 cohort studies (42 to 1 006 398 participants). Snus use during pregnancy probably (moderate confidence in risk estimates) increase the risk of neonatal apnea, adjusted odds ratio 95% confidence interval [aOR (95% CI)] 1.96 (1.30 to 2.96). Snus use during pregnancy possibly (low confidence in risk estimates) increase the risk of stillbirths aOR 1.43 (1.02 to 1.99), extremely premature births aOR 1.69 (1.17 to 2.45), moderately premature birth aOR 1.26 (1.15 to 1.38), SGA aOR 1.26 (1.09 to 1.46), reduced birth weight mean difference of 72.47 g (110.58 g to 34.35 g reduction) and oral cleft malformations aOR 1.48 (1.00 to 2.21). It is uncertain (low confidence in risk estimates, CI crossing 1) whether snus use during pregnancy affects risk of preeclampsia aOR 1.11 (0.97 to 1.28), antenatal bleeding aOR 1.15 (0.92 to 1.44) and very premature birth aOR 1.26 (0.95 to 1.66). Risk of early neonatal mortality and altered heart rate variability is uncertain, very low confidence. Snus using mothers had increased prevalence of caesarean sections, low confidence. This systematic review reveals that use of smokeless tobacco (snus) during pregnancy may adversely impact the developing child.
Sections du résumé
BACKGROUND AND AIMS
Smokeless tobacco is a heterogeneous product group with diverse composition and prevalence globally. Tobacco use during pregnancy is concerning due to the risk of adverse pregnancy outcomes and effects on child health. Nicotine may mediate several of these effects. This systematic review measured health outcomes from Swedish smokeless tobacco (snus) use during pregnancy.
METHOD
Literature search was conducted by an information specialist in May 2022. We included human studies of snus use during pregnancy compared with no tobacco use, assessed risk of bias, conducted a meta-analysis and assessed confidence in effect-estimates using Grading of Recommendations, Assessment, Development and Evaluations (GRADE).
RESULTS
We included 18 cohort studies (42 to 1 006 398 participants). Snus use during pregnancy probably (moderate confidence in risk estimates) increase the risk of neonatal apnea, adjusted odds ratio 95% confidence interval [aOR (95% CI)] 1.96 (1.30 to 2.96). Snus use during pregnancy possibly (low confidence in risk estimates) increase the risk of stillbirths aOR 1.43 (1.02 to 1.99), extremely premature births aOR 1.69 (1.17 to 2.45), moderately premature birth aOR 1.26 (1.15 to 1.38), SGA aOR 1.26 (1.09 to 1.46), reduced birth weight mean difference of 72.47 g (110.58 g to 34.35 g reduction) and oral cleft malformations aOR 1.48 (1.00 to 2.21). It is uncertain (low confidence in risk estimates, CI crossing 1) whether snus use during pregnancy affects risk of preeclampsia aOR 1.11 (0.97 to 1.28), antenatal bleeding aOR 1.15 (0.92 to 1.44) and very premature birth aOR 1.26 (0.95 to 1.66). Risk of early neonatal mortality and altered heart rate variability is uncertain, very low confidence. Snus using mothers had increased prevalence of caesarean sections, low confidence.
CONCLUSIONS
This systematic review reveals that use of smokeless tobacco (snus) during pregnancy may adversely impact the developing child.
Substances chimiques
Nicotine
6M3C89ZY6R
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
789-803Informations de copyright
© 2023 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction.
Références
International Agency for Research on Cancer (IARC) Working Group on the Evaluation of Carcinogenic Risks to Humans. Smokeless Tobacco and Some Tobacco-Specific n-Nitrosamines, IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, no. 89 Lyon, France: IARC; 2007.
The Public Health Agency of Sweden. Public Health Data. Solna, Sweden: The Public Health Agency of Sweden; 2021.
The Swedish National Board of Health and Welfare. Statistics on Pregnancies, Deliveries and Newborn Infants. 2020. Available at: http://sdb.socialstyrelsen.se/if_mfr_004/val.aspx. Accessed 2022.
Statistics Norway. Table 07692: Daily snus users and occasional snus users (per cent), by sex, age, statistical variable and year. Oslo, Norway: Statistics Norway; 2021. Available at: https://www.ssb.no/statbank/table/07692/tableViewLayout1/. Accessed 2022.
Norwegian Public Health Institute; Norwegian Medical Birth Register. Maternal snus habits in the beginning and end of pregnancy. 2021. Available at: http://statistikkbank.fhi.no/mfr/. Accessed 2022.
Cheng YC, Rostron BL, Day HR, Stanton CA, Hull LC, Persoskie A, et al. Patterns of use of smokeless tobacco in US adults, 2013-2014. Am J Public Health. 2017;107:1508-14.
Delnevo CD, Wackowski OA, Giovenco DP, Manderski MT, Hrywna M, Ling PM. Examining market trends in the United States smokeless tobacco use: 2005-2011. Tob Control. 2014;23:107-12.
Cornelius ME, Loretan CG, Wang TW, Jamal A, Homa DM. Tobacco product use among adults-United States, 2020. Morb Mortal Wkly Rep. 2022;71:397-405.
National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health. The Health Consequences of Smoking-50 years of Progress: a Report of the Surgeon General. Atlanta, GA: Centers for Disease Control and Prevention; 2014.
Lambers DS, Clark KE. The maternal and fetal physiologic effects of nicotine. Semin Perinatol. 1996;20:115-26.
Lauterstein DE, Tijerina PB, Corbett K, Akgol OB, Shen SS, Gordon T, et al. Frontal cortex transcriptome analysis of mice exposed to electronic cigarettes during early life stages. Int J Environ Res Public Health. 2016;13:417.
McGrath-Morrow SA, Hayashi M, Aherrera A, Lopez A, Malinina A, Collaco JM, et al. The effects of electronic cigarette emissions on systemic cotinine levels, weight and postnatal lung growth in neonatal mice. PLOS ONE. 2015;10:e0118344.
Zelikoff JT, Parmalee NL, Corbett K, Gordon T, Klein CB, Aschner M. Microglia activation and gene expression alteration of neurotrophins in the hippocampus following early-life exposure to E-cigarette aerosols in a murine model. Toxicol Sci. 2018;162:276-86.
National Center for Chronic Disease Prevention, Health Promotion Office on Smoking and Health. Publications and Reports of the Surgeon General. E-cigarette use Among Youth and Young Adults: A Report of The Surgeon General Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2016.
Holloway AC, Salomon A, Soares MJ, Garnier V, Raha S, Sergent F, et al. Characterization of the adverse effects of nicotine on placental development: in vivo and in vitro studies. Am J Physiol Endocrinol Metab. 2014;306:E443-56.
Suter MA, Aagaard KM. The impact of tobacco chemicals and nicotine on placental development. Prenat Diagn. 2020;40:1193-200.
Luck W, Nau H. Exposure of the fetus, neonate, and nursed infant to nicotine and cotinine from maternal smoking. N Engl J Med. 1984;311:672.
Dahlström A, Ebersjö C, Lundell B. Nicotine exposure in breastfed infants. Acta Paediatr. 2004;93:810-6.
Nordenstam F, Lundell B, Edstedt Bonamy A-K, Raaschou P, Wickström R. Snus users had high levels of nicotine, cotinine and 3-hydroxycotinine in their breastmilk, and the clearance was slower than in smoking mothers. Acta Paediatr. 2019;108:1250-5.
Nordhagen LS, Kreyberg I, Bains KES, Carlsen KH, Glavin K, Skjerven HO, et al. Maternal use of nicotine products and breastfeeding 3 months postpartum. Acta Paediatr. 2020;109:2594-603.
Hukkanen J, Jacob P III, Benowitz NL. Metabolism and disposition kinetics of nicotine. Pharmacol Rev. 2005;57:79-115.
Furlan AD, Pennick V, Bombardier C, van Tulder M. 2009 updated method guidelines for Systematic Reviews in the Cochrane Back Review Group. Spine (Phila PA 1976). 2009;34:929-1941.
Folkehelseinstituttet. Helserisiko ved snusbruk [Health risks From Snus Use. Norwegian Institute of Public Health. Report 2019], versjon 2. Folkehelseinstituttet Rapport 2019. Oslo, Norway: Folkehelseinstituttet; 2019.
Folkehelseinstituttet. Helserisiko ved snusbruk [Health risks from Snus Use. Norwegian Institute of Public Health. Report 2014]. Folkehelseinstituttet Rapport 2014. Oslo, Norway: Folkehelseinstituttet; 2014.
Natvig NI, Dybing E, Gilljam H, Lind PO, Lund KE, Mørland J, et al. NIPH systematic reviews: Executive Summaries. Health Effects and Dependency Associated With Snuff Consumption Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2005.
Godlee F, Malone R, Timmis A, Otto C, Bush A, Pavord I, et al. Journal policy on research funded by the tobacco industry. BMJ. 2013;347:f5193.
The Joanna Briggs Institute (JBI). Critical Appraisal Tools for Cohort Studies. Adelaide, Australia: JBI, Faculty of Health Sciences, University of Adelaide; 2020.
Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schünemann HJ. What is ‘quality of evidence’ and why is it important to clinicians? BMJ. 2008;336:995-8.
Kreyberg I, Hilde K, Bains KES, Carlsen K-H, Granum B, Haugen G, et al. Snus in pregnancy and infant birth size: a mother-child birth cohort study. ERJ Open Res. 2019;5:00255-02019.
Rygh E, Gallefoss F, Grøtvedt L. Trends in maternal use of snus and smoking tobacco in pregnancy. A register study in southern Norway. BMC Pregnancy Childbirth. 2019;19:500-0.
Lundholm C, Gunnerbeck A, D'Onofrio BM, Larsson H, Pershagen G, Almqvist C. Smoking and snuff use in pregnancy and the risk of asthma and wheeze in pre-schoolchildren-a population-based register study. Clin Exp Allergy. 2020;50:597-608.
Madley-Dowd P, Lundberg M, Heron J, Zammit S, Ahlqvist VH, Magnusson C, et al. Maternal smoking and smokeless tobacco use during pregnancy and offspring development: sibling analysis in an intergenerational Swedish cohort. Int J Epidemiol. 2022;50:1840-51.
Nordenstam F, Norman M, Wickström R. Blood pressure and heart rate variability in preschool children exposed to smokeless tobacco in fetal life. J Am Heart Assoc. 2019;8:e012629.
Baba S, Wikström AK, Stephansson O, Cnattingius S. Influence of smoking and snuff cessation on risk of preterm birth. Eur J Epidemiol. 2012;27:297-304.
Baba S, Wikström AK, Stephansson O, Cnattingius S. Changes in snuff and smoking habits in Swedish pregnant women and risk for small for gestational age births. Br J Obstet Gynaecol. 2013;120:456-62.
Baba S, Wikström AK, Stephansson O, Cnattingius S. Influence of snuff and smoking habits in early pregnancy on risks for stillbirth and early neonatal mortality. Nicotine Tob Res. 2014;16:78-83.
Dahlin S, Gunnerbeck A, Wikström AK, Cnattingius S, Edstedt Bonamy AK. Maternal tobacco use and extremely premature birth-a population-based cohort study. Br J Obstet Gynaecol. 2016;123:1938-46.
England LJ, Levine RJ, Mills JL, Klebanoff MA, Yu KF, Cnattingius S. Adverse pregnancy outcomes in snuff users. Am J Obstet Gynecol. 2003;189:939-43.
Gunnerbeck A, Wikström AK, Bonamy AK, Wickström R, Cnattingius S. Relationship of maternal snuff use and cigarette smoking with neonatal apnea. Pediatrics. 2011;128:503-9.
Gunnerbeck A, Edstedt Bonamy AK, Wikström AK, Granath F, Wickström R, Cnattingius S. Maternal snuff use and smoking and the risk of oral cleft malformations-a population-based cohort study. PLOS ONE. 2014;9:e84715.
Juárez SP, Merlo J. The effect of Swedish snuff (snus) on offspring birthweight: a sibling analysis. PLOS ONE. 2013;8:e65611.
Nordenstam F, Lundell B, Cohen G, Tessma MK, Raaschou P, Wickström R. Prenatal exposure to snus alters heart rate variability in the infant. Nicotine Tob Res. 2017;19:797-803.
Wikström AK, Cnattingius S, Galanti MR, Kieler H, Stephansson O. Effect of Swedish snuff (snus) on preterm birth. Br J Obstet Gynaecol. 2010;117:1005-10.
Wikström AK, Cnattingius S, Stephansson O. Maternal use of Swedish snuff (snus) and risk of stillbirth. Epidemiology. 2010;21:772-8.
Wikström AK, Stephansson O, Cnattingius S. Tobacco use during pregnancy and preeclampsia risk: effects of cigarette smoking and snuff. Hypertension. 2010;55:1254-9.
Wikman A, Axfors C, Iliadis SI, Cox J, Fransson E, Skalkidou A. Characteristics of women with different perinatal depression trajectories. J Neurosci Res. 2020;98:1268-82.
Källén B, Källén K. The Swedish Medical Birth Register-a summary of content and quality Stockholm, Sweden: Socialstyrelsen [Swedish National Board of Health and Welfare]; 2003.
England LJ, Aagaard K, Bloch M, Conway K, Cosgrove K, Grana R, et al. Developmental toxicity of nicotine: a transdisciplinary synthesis and implications for emerging tobacco products. Neurosci Biobehav Rev. 2017;72:176-89.
Coleman T, Cooper S, Thornton JG, Grainge MJ, Watts K, Britton J, et al. A randomized trial of nicotine-replacement therapy patches in pregnancy. N Engl J Med. 2012;366:808-18.
Berlin I, Grangé G, Jacob N, Tanguy ML. Nicotine patches in pregnant smokers: randomised, placebo controlled, multicentre trial of efficacy. BMJ. 2014;348:g1622.
Claire R, Chamberlain C, Davey MA, Cooper SE, Berlin I, Leonardi-Bee J, et al. Pharmacological interventions for promoting smoking cessation during pregnancy. Cochrane Database Syst Rev. 2020;3:CD010078.
Inamdar AS, Croucher RE, Chokhandre MK, Mashyakhy MH, Marinho VC. Maternal smokeless tobacco use in pregnancy and adverse health outcomes in newborns: a systematic review. Nicotine Tob Res. 2015;17:1058-66.
Gunnerbeck A, Raaschou P, Cnattingius S, Edstedt Bonamy AK, Wickström R. Maternal snuff use and cotinine in late pregnancy-a validation study. Acta Obstet Gynecol Scand. 2018;97:1373-80.
Benowitz NL, Gourlay SG. Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy. J Am Coll Cardiol. 1997;29:1422-31.
Sjoberg N, Saint DA. A single 4 mg dose of nicotine decreases heart rate variability in healthy nonsmokers: implications for smoking cessation programs. Nicotine Tob Res. 2011;13:369-72.
Moheimani RS, Bhetraratana M, Peters KM, Yang BK, Yin F, Gornbein J, et al. Sympathomimetic effects of acute E-cigarette use: role of nicotine and non-nicotine constituents. J Am Heart Assoc. 2017;6:e006579.
Lawler TS, Stanfill SB, Tran HT, Lee GE, Chen PX, Kimbrell JB, et al. Chemical analysis of snus products from the United States and northern Europe. PLOS ONE. 2020;15:e0227837.
Holme JA, Valen H, Brinchmann BC, Vist GE, Grimsrud TK, Becher R, et al. Polycyclic aromatic hydrocarbons (PAHs) may explain the paradoxical effects of cigarette use on preeclampsia (PE). Toxicology. 2022;473:153206.
Becher R, Valen H, Vist GE, Brinchmann BC, Holme JA, Grimsrud TK, et al. Adverse health effects of electronic cigarette use: an umbrella review and toxicological evaluation. Norwegian Institute of Public Health; 2022. Available at: https://www.fhi.no/publ/2022/adverse-health-effects-of-electronic-cigarette-use-an-umbrella-review-and-t/. Accessed 2022.